Literature DB >> 21775688

Using prothrombin complex concentrates to rapidly reverse oral anticoagulant effects.

William E Dager1.   

Abstract

Warfarin is a commonly prescribed anticoagulant that may, in selected situations, require rapid reversal of its effects. Several approaches to achieve reversal have been explored, including the administration of prothrombin complex concentrates (PCCs), Many factors can influence determination of an appropriate PCC dose and the resulting effects. Considerations on the use of PCC products to expedite the reversal of warfarin are described.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21775688     DOI: 10.1345/aph.1Q288

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  5 in total

1.  Reversal of anticoagulation with four-factor prothrombin complex concentrate without concurrent vitamin K (phytonadione) for urgent surgery in a patient at moderate-to-high risk for thromboembolism.

Authors:  Thomas Michael Farley; Elisha M Andreas
Journal:  BMJ Case Rep       Date:  2016-10-27

2.  Pharmacotherapy Pearls for Emergency Neurological Life Support.

Authors:  Gretchen M Brophy; Theresa Human
Journal:  Neurocrit Care       Date:  2017-09       Impact factor: 3.210

3.  Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors.

Authors:  Betsy Karli; Billie Bartel; Rachel Pavelko
Journal:  Hosp Pharm       Date:  2015-07-31

Review 4.  Emergency Neurological Life Support: Pharmacotherapy.

Authors:  Gretchen M Brophy; Theresa Human; Lori Shutter
Journal:  Neurocrit Care       Date:  2015-12       Impact factor: 3.532

5.  Positive Patient Postoperative Outcomes with Pharmacotherapy: A Narrative Review including Perioperative-Specialty Pharmacist Interviews.

Authors:  Richard H Parrish; Heather Monk Bodenstab; Dustin Carneal; Ryan M Cassity; William E Dager; Sara J Hyland; Jenna K Lovely; Alyssa Pollock; Tracy M Sparkes; Siu-Fun Wong
Journal:  J Clin Med       Date:  2022-09-24       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.